191285-93-5

Basic information

• Product Name: 1H-Imidazol-1-yloxy, 4,5-dihydro-2-(4-methoxyphenyl)-4,4,5,5-tetramethyl-
• CAS NO: 191285-93-5
• Molecular Formula: C14H19N2O2
• Molecular Weight: 247.317
• Mol File: 191285-93-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1H-Imidazol-1-yloxy, 4,5-dihydro-2-(4-methoxyphenyl)-4,4,5,5-tetramethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Imidazol-1-yloxy, 4,5-dihydro-2-(4-methoxyphenyl)-4,4,5,5-tetramethyl-(191285-93-5)
• EPA Substance Registry System: 1H-Imidazol-1-yloxy, 4,5-dihydro-2-(4-methoxyphenyl)-4,4,5,5-tetramethyl-(191285-93-5)

Safety Data

• Hazardous Substances Data: 191285-93-5(Hazardous Substances Data)

Upstream product

• 123-11-5 4-methoxy-benzaldehyde 
• 41359-25-5 1,3-dihydroxyl-2-(4'-methoxyphen-1'-yl)-4,4,5,5-tetramethylimidazolidine 
• 117566-76-4 2-methoxyphenyl-4,4,5,5-tetramethyl-4,5-dihydro-1H-imidazolyl-1-oxy 3-oxide 

Downstream Products

• 735278-99-6 1-(acetyloxy)-2-(4-methoxyphenyl)-4,4,5,5-tetramethyl-4,5-dihydro-1H-imidazole 
• 735279-06-8 1,4,4,5,5-pentamethyl-2-(4-methoxyphenyl)-4,5-dihydro-1H-imidazole 3-oxide 
• 735278-76-9 2-(4-methoxyphenyl)-4,4,5,5-tetramethyl-4,5-dihydro-1H-imidazol-1-ol 

Relevant articles and documents

Novel 1-oxyl-2-substitutedphenyl-4,4,5,5-tetramethylimidazolines: Synthesis, selectively analgesic action, and QSAR analysis

Based on the knowledge that imidazoline can result in analgesic action due to its selective binding with the prostacyclin receptor, 20 1-oxyl-2-substitutedphenyl-4,4,5,5-tetramethylimidazolines (3a-t) were prepared in moderate yields. At 0.13 mmol/kg dose, their in vivo analgesic activities were evaluated after the mice were administered at 30, 60, 90, and 150 min. Compared with the pain threshold (12.27 ± 9.56-17.71 ± 7.00%) of normal saline (NS) receiving mice, the pain threshold (23.42 ± 8.14% to 102.58 ± 10.66%) of 3a-t receiving mice increases significantly. Considering a prostacyclin receptor targeting analgesic agent usually had bleeding action and to appraise the bleeding risk, the in vivo tail bleeding time of 1.30 mmol/kg 3a-t receiving mice was found to be ranged from 116.3 ± 8.2 s to 120.3 ± 9.2 s, which was substantially equal to that (117.8 ± 8.4 s to 119.0 ± 8.6 s) of NS receiving mice. Based on the possibility of imidazoline acting as vasodilator, the in vitro vasorelaxations of 3a-t were tested using the rat aortic strip model. When the aortic strip contracted by noradrenaline (NE, final concentration 10-7 mol/l) was treated with 3a-t (final concentration 5 × 10-4 mol/l), only lower percentage inhibitions (6.55 ± 5.70-37.40 ± 4.07%) were recorded, implying that the vasorelaxation of 3a-t was neglectable. By selecting appropriate molecular descriptors generated from e-dragon server, the QSAR model of the analgesic activities of 3a-t was constructed using the multiple linear regression method. The established QSAR model showed reasonable accuracy and thus it is promising to be used for screening new 1-oxyl-2-substitutedphenyl-4,4,5,5-tetramethylimidazoline derivatives as analgesic agents.

SUBSTITUENT EFFECT ON THE REACTION OF 2-(SUBSTITUTED PHENYL)-4,5-DIHYDRO-4,4,5,5-TETRAMETHYLIMIDAZOL-1-OXYL 3-OXIDES WITH NITRIC OXIDE: AN EXPERIMENTAL AND MNDO STUDY

The relative rate constants of the oxygen transfer reaction of 2-(substituted phenyl)-4,5-dihydro-4,4,5,5-tetramethylimidazol-1-oxyl 3-oxides with nitric acid have been measured by using liquid chromatography (h.p.l.c.).The Hammett ρ value (-0.37) indicates that electron-donating substituents favour the reaction.This can be explained by a mechanism which includes electron transfer to nitric oxide and can be rationalised by frontier orbital energies and electron densities on the nitroxyl oxygen calculated by semiempirical MNDO methods.